Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 11/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25405239 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KDM2BSMN1; SMN2KDM4EPKM | |
| SCHEMBL12023144 | 0.82 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL9912673 | 0.81 | BCHE (0.38) | ALDH1A1SMN1; SMN2KDM4EPKMMEN1 | |
| SCHEMBL971781 | 0.79 | HPGD (0.40) | ALDH1A1SMN1; SMN2BCHE | |
| SCHEMBL2847700 | 0.79 | HPGD (0.40) | ALDH1A1SMN1; SMN2BCHE | |
| SCHEMBL3322339 | 0.79 | HPGD (0.40) | ALDH1A1SMN1; SMN2BCHE | |
| SCHEMBL3964578 | 0.78 | BCHE (0.36) | ALDH1A1KDM2BKDM4EMEN1KMT2A | |
| SCHEMBL19798957 | 0.77 | BCHE (0.35) | ALDH1A1KDM4EMEN1KMT2ABCHE | |
| SCHEMBL8242669 | 0.77 | BCHE (0.35) | ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL19814636 | 0.77 | KDM2B (0.51) | ALDH1A1KDM2BSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4493556-A1 | NLRP3 MODULATORS | Zomagen Biosciences Ltd (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-2023178099-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295113-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD | 2023-09-21 | — | — | US | disclosed |
| US-20230295113-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295113-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | ALDH1A1 2633/4885KDM2B 4280/4885SMN1; SMN2 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.